Ionis Pharmaceuticals IONS Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss?
- Ionis Pharmaceuticals (IONS) reported debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss of $2.71M in Q1 2026.
- How has Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss changed year-over-year?
- Ionis Pharmaceuticals's debt securities, available-for-sale, continuous unrealized loss position, less than 12 months, accumulated loss increased by 64.1% year-over-year, from $1.65M to $2.71M.